DXBHealth CareCompany Update16 Oct 202616 October 2026· 2 min read
Dimerix (ASX: DXB) Clears 100-Patient Phase 3 Treatment Mark
The first 100 patients have completed two years of blinded treatment in Dimerix’s ACTION3 Phase 3 trial. Of those participants, 93 entered the open-label extension study.